Western Europe Asia Latin America North America
| Best M&A deal |
| Novartis |
|
Deal type: acquisition of Lek Amount: e876 million Date: October 2002 Advisers: Bank Austria (Novartis), ABN Amro (Lek) |
|
Lek: its production capacity and |
Some of the biggest pharmaceutical companies have been exiting from the generics business but Novartis has made it clear that it intends to expand its share. The world’s second-biggest pharmaceuticals company believes that the patent explosion of the past five years is slowing, and that a good toehold in generics will help it to undercut rivals, particularly arch-rival GlaxoSmithKline (GSK), the biggest pharmaceuticals company.
Access intelligence that drives action
To unlock this research, enter your email to log in or enquire about access
